Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance
- 6 January 2025
- journal article
- review article
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (3) , 303-321
Abstract
Aims This review examines the challenges posed by Diabetic Foot Infections (DFIs), focusing on the impact of neuropathy, peripheral arterial disease, immunopathy, and the polymicrobial nature of these infections. The aim is to explore the factors contributing to antimicrobial resistance and assess the potential of novel antimicrobial treatments and drug delivery systems in improving patient outcomes. Method A comprehensive analysis of existing literature on DFIs was conducted, highlighting the multifactorial pathogenesis and polymicrobial composition of these infections. The review delves into the rise of antimicrobial resistance due to the overuse of antimicrobials, biofilm formation, and microbial genetic adaptability. Additionally, it considers glycemic control, patient adherence, and recurrence rates as contributing factors to treatment failure. Emerging therapies, including new antimicrobial classes and innovative drug delivery systems, were evaluated for their potential efficacy. Results DFIs present unique treatment challenges, with high rates of antimicrobial resistance and poor response to standard therapies. Biofilm formation and the genetic adaptability of pathogens worsen resistance, complicating treatment. Current antimicrobial therapies are further hindered by poor glycemic control and patient adherence, leading to recurrent infections. Novel antimicrobial classes and innovative delivery systems show promise in addressing these challenges by offering more targeted, effective treatments. These new approaches aim to reduce resistance and improve treatment outcomes. Conclusion DFIs remain a clinical challenge due to their multifactorial nature and antimicrobial resistance. The development of novel antimicrobials and drug delivery systems is crucial to improving patient outcomes and combating resistance. Future research should focus on enhancing treatment efficacy, reducing resistance, and addressing patient adherence to reduce the burden of DFIs.Keywords
This publication has 111 references indexed in Scilit:
- Magnetic nanoparticles for theragnosticsAdvanced Drug Delivery Reviews, 2009
- Comprehensive Foot Examination and Risk AssessmentDiabetes Care, 2008
- Biofilms in chronic woundsWound Repair and Regeneration, 2007
- Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial StewardshipClinical Infectious Diseases, 2007
- Role of Hyaluronidase in Subcutaneous Spread and Growth of Group A StreptococcusInfection and Immunity, 2006
- Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infectionsJournal of Antimicrobial Chemotherapy, 2005
- Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infectionsJournal of Antimicrobial Chemotherapy, 2005
- Diabetes and AtherosclerosisJAMA, 2002
- Wound Microbiology and Associated Approaches to Wound ManagementClinical Microbiology Reviews, 2001
- An Assessment of Clinical Wound Evaluation ScalesAcademic Emergency Medicine, 1998